Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial
[EN]The purpose of this study was to confirm overall survival (OS) and other clinical benefits with bortezomib, melphalan, and prednisone (VMP) versus melphalan and prednisone (MP) in the phase III VISTA (Velcade as Initial Standard Therapy in Multiple Myeloma) trial after prolonged follow-up, and e...
| Autores: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2010 |
| País: | España |
| Institución: | Universidad de Salamanca (USAL) |
| Repositorio: | GREDOS. Repositorio Institucional de la Universidad de Salamanca |
| OAI Identifier: | oai:gredos.usal.es:10366/154346 |
| Acceso en línea: | http://hdl.handle.net/10366/154346 |
| Access Level: | acceso abierto |
| Palabra clave: | Mieloma múltiple Aged Boronic Acids Kaplan-Meier Estimate Risk Assessment Humans Pyrazines Melphalan Antineoplastic Combined Chemotherapy Protocols Recurrence Multiple Myeloma Time Factors Risk Factors Treatment Outcome Prednisone protocolos de quimioterapia antineoplásica combinada humanos factores de tiempo anciano mieloma múltiple factores de riesgo prednisona ácidos borónicos resultado del tratamiento recurrencia evaluación de riesgos piracinas estimación de Kaplan-Meier melfalán |
| id |
ES_e06f84e839daee90f2d7e73ddac3017d |
|---|---|
| oai_identifier_str |
oai:gredos.usal.es:10366/154346 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trialMateos Manteca, María VictoriaRichardson, Paul G.Schlag, RudolfKhuageva, Nuriet KDimopoulos, Meletios A.Shpilberg, OferKropff, MartinSpicka, IvanPetrucci, Maria TPalumbo, AntonioSamoilova, Olga SDmoszynska, AnnaAbdulkadyrov, Kudrat MSchots, RikJiang, BinEsseltine, Dixie-LeeLiu, KevinCakana, Andrewvan de Velde, HelgiSan Miguel Izquierdo, Jesús FernandoMieloma múltipleAgedBoronic AcidsKaplan-Meier EstimateRisk AssessmentHumansPyrazinesMelphalanAntineoplastic Combined Chemotherapy ProtocolsRecurrenceMultiple MyelomaTime FactorsRisk FactorsTreatment OutcomePrednisoneprotocolos de quimioterapia antineoplásica combinadahumanosfactores de tiempoancianomieloma múltiplefactores de riesgoprednisonaácidos borónicosresultado del tratamientorecurrenciaevaluación de riesgospiracinasestimación de Kaplan-Meiermelfalán[EN]The purpose of this study was to confirm overall survival (OS) and other clinical benefits with bortezomib, melphalan, and prednisone (VMP) versus melphalan and prednisone (MP) in the phase III VISTA (Velcade as Initial Standard Therapy in Multiple Myeloma) trial after prolonged follow-up, and evaluate the impact of subsequent therapies. Previously untreated symptomatic patients with myeloma ineligible for high-dose therapy received up to nine 6-week cycles of VMP (n = 344) or MP (n = 338). With a median follow-up of 36.7 months, there was a 35% reduced risk of death with VMP versus MP (hazard ratio, 0.653; P < .001); median OS was not reached with VMP versus 43 months with MP; 3-year OS rates were 68.5% versus 54.0%. Response rates to subsequent thalidomide- (41% v 53%) and lenalidomide-based therapies (59% v 52%) appeared similar after VMP or MP; response rates to subsequent bortezomib-based therapy were 47% versus 59%. Among patients treated with VMP (n = 178) and MP (n = 233), median survival from start of subsequent therapy was 30.2 and 21.9 months, respectively, and there was no difference in survival from salvage among patients who received subsequent bortezomib, thalidomide, or lenalidomide. Rates of adverse events were higher with VMP versus MP during cycles 1 to 4, but similar during cycles 5 to 9. With VMP, 79% of peripheral neuropathy events improved within a median of 1.9 months; 60% completely resolved within a median of 5.7 months. VMP significantly prolongs OS versus MP after lengthy follow-up and extensive subsequent antimyeloma therapy. First-line bortezomib use does not induce more resistant relapse. VMP used upfront appears more beneficial than first treating with conventional agents and saving bortezomib- and other novel agent-based treatment until relapse.American Society of Clinical Oncology202420242010info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://hdl.handle.net/10366/154346reponame:GREDOS. Repositorio Institucional de la Universidad de Salamancainstname:Universidad de Salamanca (USAL)Inglésinfo:eu-repo/semantics/openAccessoai:gredos.usal.es:10366/1543462026-06-07T06:28:51Z |
| dc.title.none.fl_str_mv |
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial |
| title |
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial |
| spellingShingle |
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial Mateos Manteca, María Victoria Mieloma múltiple Aged Boronic Acids Kaplan-Meier Estimate Risk Assessment Humans Pyrazines Melphalan Antineoplastic Combined Chemotherapy Protocols Recurrence Multiple Myeloma Time Factors Risk Factors Treatment Outcome Prednisone protocolos de quimioterapia antineoplásica combinada humanos factores de tiempo anciano mieloma múltiple factores de riesgo prednisona ácidos borónicos resultado del tratamiento recurrencia evaluación de riesgos piracinas estimación de Kaplan-Meier melfalán |
| title_short |
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial |
| title_full |
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial |
| title_fullStr |
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial |
| title_full_unstemmed |
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial |
| title_sort |
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial |
| dc.creator.none.fl_str_mv |
Mateos Manteca, María Victoria Richardson, Paul G. Schlag, Rudolf Khuageva, Nuriet K Dimopoulos, Meletios A. Shpilberg, Ofer Kropff, Martin Spicka, Ivan Petrucci, Maria T Palumbo, Antonio Samoilova, Olga S Dmoszynska, Anna Abdulkadyrov, Kudrat M Schots, Rik Jiang, Bin Esseltine, Dixie-Lee Liu, Kevin Cakana, Andrew van de Velde, Helgi San Miguel Izquierdo, Jesús Fernando |
| author |
Mateos Manteca, María Victoria |
| author_facet |
Mateos Manteca, María Victoria Richardson, Paul G. Schlag, Rudolf Khuageva, Nuriet K Dimopoulos, Meletios A. Shpilberg, Ofer Kropff, Martin Spicka, Ivan Petrucci, Maria T Palumbo, Antonio Samoilova, Olga S Dmoszynska, Anna Abdulkadyrov, Kudrat M Schots, Rik Jiang, Bin Esseltine, Dixie-Lee Liu, Kevin Cakana, Andrew van de Velde, Helgi San Miguel Izquierdo, Jesús Fernando |
| author_role |
author |
| author2 |
Richardson, Paul G. Schlag, Rudolf Khuageva, Nuriet K Dimopoulos, Meletios A. Shpilberg, Ofer Kropff, Martin Spicka, Ivan Petrucci, Maria T Palumbo, Antonio Samoilova, Olga S Dmoszynska, Anna Abdulkadyrov, Kudrat M Schots, Rik Jiang, Bin Esseltine, Dixie-Lee Liu, Kevin Cakana, Andrew van de Velde, Helgi San Miguel Izquierdo, Jesús Fernando |
| author2_role |
author author author author author author author author author author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
Mieloma múltiple Aged Boronic Acids Kaplan-Meier Estimate Risk Assessment Humans Pyrazines Melphalan Antineoplastic Combined Chemotherapy Protocols Recurrence Multiple Myeloma Time Factors Risk Factors Treatment Outcome Prednisone protocolos de quimioterapia antineoplásica combinada humanos factores de tiempo anciano mieloma múltiple factores de riesgo prednisona ácidos borónicos resultado del tratamiento recurrencia evaluación de riesgos piracinas estimación de Kaplan-Meier melfalán |
| topic |
Mieloma múltiple Aged Boronic Acids Kaplan-Meier Estimate Risk Assessment Humans Pyrazines Melphalan Antineoplastic Combined Chemotherapy Protocols Recurrence Multiple Myeloma Time Factors Risk Factors Treatment Outcome Prednisone protocolos de quimioterapia antineoplásica combinada humanos factores de tiempo anciano mieloma múltiple factores de riesgo prednisona ácidos borónicos resultado del tratamiento recurrencia evaluación de riesgos piracinas estimación de Kaplan-Meier melfalán |
| description |
[EN]The purpose of this study was to confirm overall survival (OS) and other clinical benefits with bortezomib, melphalan, and prednisone (VMP) versus melphalan and prednisone (MP) in the phase III VISTA (Velcade as Initial Standard Therapy in Multiple Myeloma) trial after prolonged follow-up, and evaluate the impact of subsequent therapies. Previously untreated symptomatic patients with myeloma ineligible for high-dose therapy received up to nine 6-week cycles of VMP (n = 344) or MP (n = 338). With a median follow-up of 36.7 months, there was a 35% reduced risk of death with VMP versus MP (hazard ratio, 0.653; P < .001); median OS was not reached with VMP versus 43 months with MP; 3-year OS rates were 68.5% versus 54.0%. Response rates to subsequent thalidomide- (41% v 53%) and lenalidomide-based therapies (59% v 52%) appeared similar after VMP or MP; response rates to subsequent bortezomib-based therapy were 47% versus 59%. Among patients treated with VMP (n = 178) and MP (n = 233), median survival from start of subsequent therapy was 30.2 and 21.9 months, respectively, and there was no difference in survival from salvage among patients who received subsequent bortezomib, thalidomide, or lenalidomide. Rates of adverse events were higher with VMP versus MP during cycles 1 to 4, but similar during cycles 5 to 9. With VMP, 79% of peripheral neuropathy events improved within a median of 1.9 months; 60% completely resolved within a median of 5.7 months. VMP significantly prolongs OS versus MP after lengthy follow-up and extensive subsequent antimyeloma therapy. First-line bortezomib use does not induce more resistant relapse. VMP used upfront appears more beneficial than first treating with conventional agents and saving bortezomib- and other novel agent-based treatment until relapse. |
| publishDate |
2010 |
| dc.date.none.fl_str_mv |
2010 2024 2024 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/10366/154346 |
| url |
http://hdl.handle.net/10366/154346 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
American Society of Clinical Oncology |
| publisher.none.fl_str_mv |
American Society of Clinical Oncology |
| dc.source.none.fl_str_mv |
reponame:GREDOS. Repositorio Institucional de la Universidad de Salamanca instname:Universidad de Salamanca (USAL) |
| instname_str |
Universidad de Salamanca (USAL) |
| reponame_str |
GREDOS. Repositorio Institucional de la Universidad de Salamanca |
| collection |
GREDOS. Repositorio Institucional de la Universidad de Salamanca |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869422202168803328 |
| score |
15,300724 |